Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication
Open Access
- 28 June 2018
- journal article
- research article
- Published by Springer Nature in BMC Psychiatry
- Vol. 18 (1) , 1-9
Abstract
Non-adherence to medication remains a major challenge in the long-term management of patients with schizophrenia. Next to lack of insight into the illness, adverse effects of antipsychotic drugs, cognitive deficits, poor therapeutic alliance, reduced quality of life, missing social support, and negative attitudes toward medication are predictors of non-adherence. This study examined potential correlations between attitudes toward antipsychotic drug therapy, subjective well-being, and symptom change in patients with chronic schizophrenia. 30 patients with schizophrenia starting monotherapy with a new-generation antipsychotic were included into the study. The Drug Attitude Inventory (DAI) and the Subjective Well-being under Neuroleptic Treatment Scale, short form (SWN-K), were administered after 2, 4, and 12 weeks of treatment. At the same points in time and at baseline, psychopathological symptoms were rated by means of the Positive and Negative Syndrome Scale (PANSS), and functioning was assessed by means of the Global Assessment of Functioning Scale (GAF). Antipsychotic induced side effects were evaluated by using the Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale. Study participants had a mean age of 37.5 ± 9.7 years, baseline symptoms were mild. The PANSS total score improved significantly from baseline to weeks 4 (p = .003) and 12 (p = .001), respectively. Neither the DAI total score nor the SWN-K total score changed significantly over the course of time. The severity of symptoms was not correlated with drug attitude at any time point but was negatively correlated with wellbeing at weeks 2 (r = −.419, p = .021) and 4 (r = −.441, p = .015). There was no significant correlation between DAI and SWN-K total scores at any time point. Next to showing that the DAI and the SWN-K measure different aspects of subjective experiences during antipsychotic treatment these findings emphasize the use of both instruments to optimize adherence to medication.Keywords
This publication has 50 references indexed in Scilit:
- Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategiesWorld Psychiatry, 2013
- DAI-10 is as good as DAI-30 in schizophreniaEuropean Neuropsychopharmacology, 2012
- Measuring Quality of Life in Patients with SchizophreniaPharmacoEconomics, 2012
- Effects and side effects of antipsychotic treatment in schizophrenia: Pros and cons of available self-rating scalesSchizophrenia Research, 2009
- Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic SchizophreniaSchizophrenia Bulletin, 2008
- Schizophrenia: Impact on quality of lifeIndian Journal of Psychiatry, 2008
- Correlation of Subjective Well-being in Schizophrenic Patients with Gait Parameters, Expert-rated Motor Disturbances, and Psychopathological StatusPharmacopsychiatry, 2005
- Measuring Quality of Life in Patients with SchizophreniaPharmacoEconomics, 1997
- A power primer.Psychological Bulletin, 1992
- Subjective well-being.Psychological Bulletin, 1984